A Phase I Trial of Combination Nab-Paclitaxel and Nintedanib or Nab-paclitaxel and Placebo in Relapsed Non-Small Cell Lung Cancer Adenocarcinoma
Status: Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 28 Aug 2019
Price : $35 *
At a glance
- Drugs Nintedanib (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- 28 Aug 2019 Last checked against ClinicalTrials.gov: US National Institutes of Health
- 22 Aug 2019 Planned initiation date changed from 1 Jun 2019 to 1 Oct 2019.
- 16 Apr 2019 Planned End Date changed from 1 Jan 2022 to 1 Jan 2023.